The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine the factors that signal the imminent development of symptomatic Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non-Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application. To accomplish these goals, HASD will assess and follow a richly phenotyped cohort that includes both cognitively normal older adults (~75%) and those with early-stage symptomatic AD (~25%). The longitudinal assessment protocol includes standard and novel clinical and cognitive measures, a six-day in-home sleep study, magnetic structural imaging studies of the brain, positron emission tomography studies of the brain to reveal the cerebral hallmarks of AD, amyloid-beta plaques and tau deposition, and examination of blood for genetic studies and of cerebrospinal fluid for levels of amyloid-beta and tau. Five Cores (Administration, Clinical, Biostatistics, Neuropathology [includes the Biofluids Laboratory], and Imaging) will support four Projects that carry out the scientific aims of HASD: Project 1: ?Characterization of Molecular Biomarker Profiles of AD throughout its Pathobiological Continuum? Project 2: ?Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer Disease? Project 3: ?Dissecting the Genetic Architecture of Resilience? Project 4: ?Smartphone-Based `Burst' Cognitive Assessments?

Public Health Relevance

The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine those factors that signal the imminent development of Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non- Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003991-37
Application #
9914167
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Hsiao, John
Project Start
1997-01-01
Project End
2024-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Roe, Catherine M; Babulal, Ganesh M; Mishra, Shruti et al. (2018) Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. J Alzheimers Dis 61:509-513
Rao, Shuquan; Ghani, Mahdi; Guo, Zhiyun et al. (2018) An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiol Aging 66:178.e1-178.e8
Laurido-Soto, Osvaldo; Brier, Matthew R; Simon, Laura E et al. (2018) Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol :
Peloso, Gina M; van der Lee, Sven J; International Genomics of Alzheimer's Project (IGAP) et al. (2018) Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimers Dement (Amst) 10:595-598
Armstrong, Richard A; McKee, Ann C; Stein, Thor D et al. (2018) Cortical degeneration in chronic traumatic encephalopathy and Alzheimer's disease neuropathologic change. Neurol Sci :
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864
Deming, Yuetiva; Li, Zeran; Benitez, Bruno A et al. (2018) Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? Expert Opin Ther Targets 22:587-598
Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075
Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590
Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98

Showing the most recent 10 out of 911 publications